JP Stock MarketDetailed Quotes

4552 JCR Pharmaceuticals

Watchlist
  • 620
  • +5+0.81%
20min DelayMarket Closed Jul 4 15:00 JST
77.38BMarket Cap14.12P/E (Static)

JCR Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

JCR Pharmaceuticals Earnings Date

Currency: JPY

Period

Q4 FY2024 Earnings

May 10, 2024

Revenue(YoY)

9.15B

+19.69%
EPS(YoY)

2.76

+71.43%
Analyst Rating

Buy

Jun 11, 2024

JCR Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 11.300B--
Jul 30, 20242025/Q1-- / 11.300B--
May 10, 20242024/Q49.153B / 12.382B--
Jan 26, 20242024/Q39.446B / 13.000B--
Oct 25, 20232024/Q213.464B / 11.000B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 11.300B--
Jul 30, 20242025/Q1-- / 11.300B--
May 10, 20242024/Q49.153B / 12.382B--
Jan 26, 20242024/Q39.446B / 13.000B--
Oct 25, 20232024/Q213.464B / 11.000B--

Unlock Free Earnings Estimates

JCR Pharmaceuticals Earnings Reports

  • JCR Pharmaceuticals: Interim report

    Jun 27 20:00 ET

  • JCR Pharmaceuticals: (Correction- Numerical Data Correction) Partial correction of the Financial results briefing[Japan Standard] (Consolidated) for the fiscal year ending March 2024.

    Jun 26 03:00 ET

  • JCR Pharmaceuticals: Confirmation letter

    Jun 26 01:12 ET

  • JCR Pharmaceuticals: Securities report - 49th period (April 1, 2023 - March 31, 2024)

    Jun 26 01:07 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jun 11, 2024

    Buy

    • Strong Buy

      28.57%

    • Buy

      0.00%

    • Hold

      71.43%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    %Chg